Genexine, Inc. (KOSDAQ:095700)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,860.00
-220.00 (-4.33%)
At close: Mar 9, 2026
17.96%
Market Cap 221.03B
Revenue (ttm) 5.81B
Net Income (ttm) -54.53B
Shares Out 45.48M
EPS (ttm) -1,320.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 567,076
Average Volume 521,216
Open 4,900.00
Previous Close 5,080.00
Day's Range 4,805.00 - 5,260.00
52-Week Range 3,510.00 - 7,190.00
Beta 0.59
RSI 55.95
Earnings Date n/a

About Genexine

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 86
Stock Exchange KOSDAQ
Ticker Symbol 095700
Full Company Profile

Financial Performance

In 2023, Genexine's revenue was 4.43 billion, a decrease of -72.57% compared to the previous year's 16.14 billion. Losses were -66.87 billion, 19.5% more than in 2022.

Financial Statements

News

There is no news available yet.